292 related articles for article (PubMed ID: 35475420)
1. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
Kosoku A; Iwai T; Uchida J
Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
[TBL] [Abstract][Full Text] [Related]
6. One-year Outcome of Everolimus With Standard-dose Tacrolimus Immunosuppression in De Novo ABO-incompatible Living Donor Kidney Transplantation: A Retrospective, Single-center, Propensity Score Matching Comparison With Mycophenolate in 42 Transplants.
Noguchi H; Tsuchimoto A; Ueki K; Kaku K; Okabe Y; Nakamura M
Transplant Direct; 2020 Jan; 6(1):e514. PubMed ID: 32047842
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
8. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
[TBL] [Abstract][Full Text] [Related]
9. Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus.
Nunes Ficher K; Dreige Y; Gessolo Lins PR; Nicolau Ferreira A; Toniato de Rezende Freschi J; Linhares K; Stopa Martins S; Custodio L; Cristelli M; Viana L; Wagner Santos D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Nakamura M; Rosso Felipe C; Medina Pestana J; Tedesco Silva H
Transplantation; 2022 Feb; 106(2):381-390. PubMed ID: 33988338
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
13. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
[TBL] [Abstract][Full Text] [Related]
14. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
[TBL] [Abstract][Full Text] [Related]
16. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
17. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
Ferreira AN; Felipe CR; Cristelli M; Viana L; Mansur J; de Paula M; Wagner D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Medina-Pestana J; Tedesco-Silva Junior H
Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
[TBL] [Abstract][Full Text] [Related]
19. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
[TBL] [Abstract][Full Text] [Related]
20. Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus.
Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
Exp Clin Transplant; 2019 Feb; 17(1):47-51. PubMed ID: 29911959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]